NC-LENOVO
28.8.2024 15:01:27 CEST | Business Wire | Press release
Lenovo (HKSE: 992) (ADR: LNVGY), the global technology powerhouse, is offering Lenovo Hybrid Cloud Advisory Services to help enterprises simplify the complexity of hybrid cloud design and create implementation-ready, future-proofed plans in as few as six weeks. Lenovo leverages four decades of experience helping global CIOs ease cloud and hybrid cloud challenges, including demands associated with emerging AI-related workloads. With the new services, Lenovo expert consultants guide enterprises through hybrid cloud needs, accelerating time to value, improving cost efficiency, and building flexibly scalable foundations.
The new era of AI is hybrid, and today’s IT organizations are converting their raw data into actionable insights with hybrid cloud solutions that are capable of harnessing data, no matter where it lives. Lenovo hybrid cloud solutions boost AI performance and agility by delivering more compute and faster memory when and where it’s needed, offering a full-stack portfolio and purpose-built solutions that are specific to each customer and use case. To support AI optimization, Lenovo Hybrid Cloud Advisory Services help design a cloud approach customized for today, and ready to flexibly scale and adapt to future needs.
“At a time when the need for modern infrastructure and solutions has never been greater, IT is challenged to evolve cloud implementations. This is evident in our most recent Lenovo global CIO report in which 82% of respondents marked cloud transformation as challenging,” said Dale Aultman, Vice President & General Manager, Hybrid Cloud Services at Lenovo Group. “We introduced Lenovo Hybrid Cloud Advisory Services to simplify cloud design strategies and pave the way for AI implementations. We bring a global team of trusted experts to help our customers develop future-proofed, tailor-made solutions to rapidly modernize hybrid clouds and ultimately deliver better business outcomes.”
Many organizations need to modernize or update their hybrid clouds due to changing business needs, spiraling costs, or performance issues. In fact, Lenovo’s third annual global CIO report found that 29% of respondents still find cloud transformation a top priority, behind AI implementation, cybersecurity, and data privacy. Demand for data center capacity continues to grow and, with increasing interest in AI, is also accelerating. IT leaders are concerned about meeting this demand due to challenges around qualified staff, procuring equipment, forecasting future requirements and energy efficiencies. Changing licensing models are also generating disruption and requiring IT leaders to lean on partners.
“Successful hybrid cloud strategy and design is imperative for enterprises, yet the underlying complexity involved cannot be understated,” said Steven Dickens, Futurum Group. “According to our research, hybrid is 2x the size of public cloud when it comes to deployment modalities for AI, therefore the need for flexibility and futureproofing becomes critical. Partnering with experts, such as Lenovo, will be the smart path forward for many enterprises.”
Lenovo Hybrid Cloud Advisory Services offers customized, strategic expertise, and a trusted partner to manage the complexity of hybrid cloud design. Lenovo experts help turn hybrid cloud vision into reality with better outcomes using customer assessment, proven methodologies, and strategic advice and approach recommendation. Lenovo’s tech-agnostic expertise, deep industry alliances and partnerships, pre-validated solutions, and experience in every aspect of hybrid cloud creation provide clear value while helping future-proof an organization’s hybrid cloud. Customer benefits include:
- Speed/Time to value
- Holistic: Cloud/software/infrastructure expertise from single provider
- End-to-end expertise
- Engineering quality
- Global presence
Lenovo Hybrid Cloud Advisory Services features a breadth of offerings that are now available, expanding Lenovo’s advisory services capabilities and complementing Lenovo’s AI services portfolio. Channel availability will launch in September 2024.
For more information regarding Lenovo Hybrid Cloud Advisory Services visit here.
About Lenovo
Lenovo is a US$57 billion revenue global technology powerhouse, ranked #248 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a full-stack portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (data center, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828812342/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom